Bykov, Vladimir J. N.
Eriksson, Sofi E.
Bianchi, Julie
Wiman, Klas G.
Article History
First Online: 15 December 2017
Competing interests
: K.G.W. and V.J.N.B. are cofounders and shareholders of Aprea Therapeutics AB, a company that develops p53-based cancer therapy, including APR-246. K.G.W. is a member of its Clinical Advisory Board. Research in the K.G.W. laboratory has financial support from Aprea Therapeutics AB. K.G.W. has received a salary from Aprea Therapeutics AB. The other authors declare no competing interests.